ReviewCurrent research in translational medicine2021
Heparin beyond anti-coagulation.
Review in Current research in translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Low molecular weight heparin decreases mortality and major complication rates in moderately severe and severe acute pancreatitis-a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Non-anticoagulant heparins: glycan-mediated immune modulation and therapeutic applications.Frontiers in immunology · 2026Review
- Association between early prophylactic heparin therapy and mortality in patients with septic shock secondary to respiratory infections: analysis based on MIMIC-IV database.BMC infectious diseases · 2025Article
- Anticoagulation therapy for intra-abdominal hypertension in patients with acute pancreatitis.BMC gastroenterology · 2025Article
- Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications.Advanced pharmaceutical bulletin · 2024Article
- Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- A novel risk stratification approach and molecular subgroup characterization based on coagulation related genes in colon adenocarcinoma.Cancer cell international · 2024Article
- The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid.Biomolecules · 2024Review
- Biomimetic polymers with phosphorylcholine groups as biomaterials for medical devices.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2024Review
- Untoward immune effects of modern medication.Journal of biomedical research · 2023Article
- Application of artificial neural network in daily prediction of bleeding in ICU patients treated with anti-thrombotic therapy.BMC medical informatics and decision making · 2023Article
- Heparin, Heparan Sulphate and Sepsis: Potential New Options for Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Biological Properties of Heparins Modified with an Arylazopyrazole-Based Photoswitch.Journal of medicinal chemistry · 2023Article
- Not Just Anticoagulation-New and Old Applications of Heparin.Molecules (Basel, Switzerland) · 2022Review
- The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term.Journal of clinical laboratory analysis · 2022Article
- Pharmacokinetic, Hemostatic, and Anticancer Properties of a Low-Anticoagulant Bovine Heparin.TH open : companion journal to thrombosis and haemostasis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin has served as a mainstream anticoagulant for over eight decades. Clinically heparin-derived compounds significantly contribute to prevention and treatment of thrombotic events complicated in numerous medical conditions such as venous thromboembolism, coronary artery disease and extracorporeal circulation processes. Moreover in recent years, various off-labeled efficacious potentials of heparin beyond anti-coagulation are dramatically emerging, and increasingly investigated in clinical studies. Herein this article presents a comprehensive update on the expanded applications of heparin agents, covering the pregnant clinic, respiratory inflammation, renal disease, sepsis, pancreatitis, among others. It aims to maximize the beneficial profile of a pharmaceutical product through medical re-purposing development, exemplified by heparin, to address the unmet clinical needs of severe illness including coronavirus disease 2019 (COVID-19).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.